Mackenbach J. P., Bos V., Andersen O. et al. Widening socioeconomic inequalities in mortality in six Western European countries // International Journal of Epidemiology. 2003. Vol. 32. P. 830–837.
McDonough P., Duncan G. J., Williams D., House J. S. Income dynamics and adult mortality in the United States, 1972 through 1989 // The American Journal of Public Health. 1997. Vol. 87. № 9. P. 1476–1483.
Britton A., Shipley M., Marmot M., Hemingway H. Does access to cardiac investigation and treatment contribute to social and ethnic differences in coronary heart disease? Whitehall II prospective cohort study // BMJ. 2004. Vol. 329. № 7461. P. 318–323.
Closing the gap in a generation: health equity through action on the social determinants of health. Final Report of the Commission on Social Determinants of Health. Geneva, World Health Organization, 2008.
Franco Á., Álvarez-Dardet C., Ruiz M. T. Effect of democracy on health: ecological study // BMJ. 2004. December 18. Vol. 329. № 7480. P. 1421–1423.
Johanson R., Newburn M., Macfarlane A. Has the medicalisation of childbirth gone too far? // BMJ. 2002. Vol. 324. № 7342. P. 892–895.
Kaunitz A. M., Spence C., Danielson T. S., Rochat R. W., Grimes D. A. Perinatal and maternal mortality in a religious group avoiding obstetric care // American Journal of Obstetrics & Gynecology. 1984. December 1. Vol. 150. № 7. P. 826–831.
Stamatakis E., Weiler R., Ioannidis J. P. Undue industry influences that distort healthcare research, strategy, expenditure and practice: a review // European journal of clinical investigation. 2013. Vol. 43. № 5. P. 469–475.
Moynihan R., Doran E., Henry D. Disease mongering is now part of the global health debate // PLoS Medicine. 2008. Vol. 5. № 5, e106.
Simons J. The $ 10 Billion Pill Hold the fries, please. Lipitor, the cholesterol-lowering drug, has become the bestselling pharmaceutical in history. Here’s how Pfizer did it // Fortune. 2003. January 20. Vol. 147. № 1. P. 58–62.
Лечение ОРВИ и гриппа в рутинной клинической практике // Фармацевтический вестник. 2017. 28 июля.
Мизерницкий Ю. Л. Применение инновационного отечественного индуктора интерферона для профилактики и лечения острых респираторных вирусных инфекций у детей // Медицинский совет. 2016. № 1. С. 50–53.
Харламова Ф. С., Кладова О. В., Сергеева Э. М. и др. Клиническая эффективность препарата Кагоцел® при гриппе и ОРВИ у детей с 2 до 6 лет // Детские инфекции. 2010. № 4. С. 34–41.
Вартанян Р. В., Сергеева Э. М., Чешик С. Г. Оценка терапевтической эффективности препарата Кагоцел® у детей младшего и дошкольного возраста с острыми респираторными вирусными инфекциями // Детские инфекции. 2011. № 1. С. 36–41.
Hill K. P., Ross J. S., Egilman D. S., Krumholz H. M. The ADVANTAGE seeding trial: A review of internal documents // Annals of Internal Medicine. 2008. Vol. 149. № 4. P. 251–258.
Krimsky S., Rothenberg L. S., Stott P., Kyle G. Scientific journals and their authors’ financial interests: A pilot study // Psychotherapy and psychosomatics. 1998. July-October. Vol. 67. № 4–5. P. 194–201.
Papanikolaou G. N., Baltogianni M. S., Contopoulos-Ioannidis D. G. et al. Reporting of conflicts of interest in guidelines of preventive and therapeutic interventions // BMC medical research methodology. 2001. Vol. P. 3.
Sismondo S. Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry? // PLoS Medicine. 2007. Vol. 4. № 9, e286.
Mirowski P., Van Horn R. The contract research organization and the commercialization of scientific research // Social studies of science. 2005. August. Vol. 35. № 4. P. 503–548.
Gubler A. Alternating hemiplegia, a sign of pontine lesion, and documentation of the proof of the facial decussation / Wolf J. K. (ed.). The Classical Brainstem Syndromes. Springfield: Charles C Thomas, 1971. P. 9–13.
Austin S. C., Stolley P. D., Lasky T. The history of malariotherapy for neurosyphilis // JAMA. 1992. Vol. 268. № 4. P. 516–519.
Valenstein E. S. Great and desparate cures: The rise and decline of psychosurgery and other radical treatments for mental illness. New York: Basic Books, 1986.
EC/IC Bypass Study Group. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial // The New England journal of medicine. 1985. November 7. Vol. 313. № 19. P. 1191–1200.
Echt D. S., Liebson P. R., Mitchell L. B. et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Supression Trial // The New England journal of medicine. 1991. March 21. Vol. 324. № 12. P. 781–788.
Moore T. J. Deadly Medicine: Why tens of thousands of heart patients died in america’s worst drug disaster. New York: Simon and Schuster, 1995.
Teo K. K., Yusuf S., Furberg C. D. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized trials // JAMA. 1993. October 6. Vol. 270. № 13. P. 1589–1595.
Eclampsia Trial Collaborative Group. Which anticonvulsant for women with eclampsia? // Lancet. 1995. June 10, Vol. 345. № 8963. P. 1455–1463.
Morgan D. J., Brownlee S., Leppin A. L., Kressin N., Dhruva S. S., Levin L. et al. Setting a research agenda for medical overuse // BMJ. 2015. August 25. Vol. 351. № 1, h4534.
Spencer I. Lessons from history: the politics of psychiatry in the USSR // Journal of Psychiatric and Mental Health Nursing. 2000. August. Vol. 7. № 4. P. 355–361.
Bloch S. Psychiatry as ideology in the USSR // Journal of medical ethics. 1978. Vol. 4. P. I26–13I.
Cochrane A. L., St Leger A. S., Moore F. Health service ‘input’ and mortality ‘output’ in developed countries // Journal of epidemiology and community health. 1978. September. Vol. 32. № 3. P. 200–205.
Carr-Hill R. A., Hardman G. F., Russell I. T. Variations in avoidable mortality and variations in health care resources // Lancet. 1987. April 4. Vol. 1. № 8536. P. 789–792.
Metcalfe D., Chowdhury R., Salim A. What are the consequences when doctors strike? // BMJ. 2015. November 25. Vol. 351. № 8035, h6231.
Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 // Lancet. 2015. January 10. Vol. 385. № 9963. P. 117–171.
Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 // Lancet. 2015. August 22. Vol. 386. № 9995. P. 743–800.
Kelly W. N. Can the frequency and risks of fatal adverse drug events be determined? // Pharmacotherapy. 2001. May. Vol. 21. № 5. P. 521–527.
Lazarou J., Pomeranz B. H., Corey P. N. Incidence of adverse drug reactions in hospitalized patients: a meta-analyses of prospective studies // JAMA. 1998. April 15. Vol. 279. № 15. P. 1200–1205.
Starfield B. Is US health really the best in the world? // JAMA. 2000. July 26. Vol. 284. № 4. P. 483–485.
Phillips D. P., Christenfeld N., Glynn L. M. Increase in US medication-error deaths between 1983 and 1993 // Lancet. 1998. February 28. Vol. 351. № 9103. P. 643–644.
Klevens R. M., Edwards J. R., Richards C. L., Horan T. C., Gaynes et al Estimating healthcare-associated infections and deaths in U. S. hospitals, 2002 // Public Health Reports. 2007. March-April. Vol. 122. № 2. P. 160–166.
Ernst F. R., Grizzle A. J. Drug-related morbidity and mortality: updating the cost-of-illness model // Journal of the American Pharmaceutical Association. 2001. March/April. Vol. 41. № 2. P. 192–199.
Johnson J. A., Boatman L. Drug-related morbidity and mortality: A Cost-of-illness model // Journal of Managed Care Pharmacy. 1996. January/February. Vol. 2. № 1. P. 39–47.
Sturkenboom M. C., Romano F., Simon G., Correa-Leite M. L., Villa M. et al. The iatrogenic costs of NSAID therapy: a population study // Arthritis and rheumatism. 2002 April 15. Vol. 47. № 2. P. 132–140.
Weingart S. N., Wilson R. McL., Gibberd R. W., Harrison B. Epidemiology of medical error // BMJ. 2000. March 18. Vol. 320. № 7237. P. 774–777.
Hayward R. A., Hofer T. P. Estimating hospital deaths due to medical errors: preventability is in the eye of the reviewer // JAMA. 2001. Vol. 286. № 4. P. 415–420.
Feldman H. A., Goldstein I., Hatzichristou D. G., Krane R. J., McKinlay J. B. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study // The Journal of urology. 1994. January. Vol. 151. № 1. P. 54–61.
Araujo A. B., Johannes C. B., Feldman H. A., Derby C. A., McKinlay J. B. Relation between psychosocial risk factors and incident erectile dysfunction: prospective results from the Massachusetts male aging study // American Journal of Epidemiology. 2000. September 15. Vol. 152. № 6. P. 533–541.
Lexchin J. Bigger and better: how Pfizer redefined erectile dysfunction // PLoS Medicine. 2006. Vol. 3. № 4, e132.
Sample I. Viagra: The profitable pill // The Guardian. 2009. November 16.
Moynihan R. The making of a disease: female sexual dysfunction // BMJ. 2003. January 4. Vol. 326. № 7379. P. 45–47.
Critser G. Generation Rx: How prescription drugs are altering American lives, minds, and bodies.